Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP

Twinbeech Capital LP lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 45.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,137 shares of the biopharmaceutical company's stock after selling 20,730 shares during the quarter. Twinbeech Capital LP's holdings in Regeneron Pharmaceuticals were worth $17,906,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $28,000. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Crowley Wealth Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC increased its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Citigroup upgraded Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the company from $600.00 to $700.00 in a research report on Wednesday, May 14th. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. The Goldman Sachs Group dropped their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Bernstein Bank dropped their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Royal Bank of Canada dropped their price objective on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $596.54 on Tuesday. The business's 50-day simple moving average is $598.10 and its 200-day simple moving average is $680.17. The firm has a market capitalization of $64.41 billion, a P/E ratio of 15.58, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $9.55 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.